Publications Print Patel BK, Carnahan MB, Northfelt D, Anderson K, Mazza GL, Pizzitola VJ, Giurescu ME, Lorans R, Eversman WG, Sharpe RE Jr, Harper LK, Apsey H, Cronin P, Kling J, Ernst B, Palmieri J, Fraker J, Mina L, Batalini F, Pockaj B. Prospective Study of Supplemental Screening With Contrast-Enhanced Mammography in Women With Elevated Risk of Breast Cancer: Results of the Prevalence Round. J Clin Oncol. 2024 Nov 10; 42 (32):3826-3836 Epub 2024 July 26 View PubMed Jahan N, Taraba J, Boddicker NJ, Giridhar KV, Leon-Ferre RA, Tevaarwerk AJ, Cathcart-Rake E, O'Sullivan CC, Peethambaram PP, Hobday TJ, Mina LA, Batalini F, Advani P, Sideras K, Haddad TC, Ruddy KJ, Goetz MP, Couch FJ, Yadav S. Real-World Evidence on Prescribing Patterns and Clinical Outcomes of Metastatic Breast Cancer Patients Treated with PARP Inhibitors: The Mayo Clinic Experience Clinical Breast Cancer. 2024. Seyedi S, Harris VK, Kapsetaki SE, Narayanan S, Saha D, Compton Z, Yousefi R, May A, Fakir E, Boddy AM, Gerlinger M, Wu C, Mina L, Huijben S, Gouge DH, Cisneros L, Ellsworth PC, Maley CC. Resistance Management for Cancer: Lessons from Farmers. Cancer Res. 2024 Oct 2 Epub 2024 Oct 02 View PubMed Murad B, Reis PCA, Deberaldini Marinho A, Marin Comini AC, Pinheiro Xavier D, Mella Soares Pessoa B, Raheem F, Ernst B, Mina LA, Batalini F. QTc prolongation across CDK4/6 inhibitors: a systematic review and meta-analysis of randomized controlled trials. JNCI Cancer Spectr. 2024 Sep 2; 8 (5) View PubMed Austin JD, James E, Perez RL, Mazza GL, Kling JM, Fraker J, Mina L, Banerjee I, Sharpe R, Patel BK. Factors influencing U.S. women's interest and preferences for breast cancer risk communication: a cross-sectional study from a large tertiary care breast imaging center. BMC Womens Health. 2024 Jun 21; 24 (1):359 Epub 2024 June 21 View PubMed Patel BK, Gurudu R, Mazza G, Sharpe RE Jr, Mina L, Fraker J, Kling JM, Anderson K, Hughes D, Pockaj B. Patient-Reported Testing Burden of Screening Contrast-Enhanced Mammography. J Am Coll Radiol. 2024 May; 21 (5):789-794 Epub 2023 Nov 11 View PubMed Seyedi S, Teo R, Foster L, Saha D, Mina L, Northfelt D, Anderson KS, Shibata D, Gatenby R, Cisneros LH, Troan B, Anderson ARA, Maley CC. Testing Adaptive Therapy Protocols Using Gemcitabine and Capecitabine in a Preclinical Model of Endocrine-Resistant Breast Cancer. Cancers (Basel). 2024 Jan 6; 16 (2) Epub 2024 Jan 06 View PubMed Raheem F, Karikalan SA, Batalini F, El Masry A, Mina L. Metastatic ER+ Breast Cancer: Mechanisms of Resistance and Future Therapeutic Approaches. Int J Mol Sci. 2023 Nov 11; 24 (22) View PubMed Batalini F, DaSilva LL, Campoverde L, Comini ACM, Carvalho BM, Nogueira W, Silveira H, Ernst BJ, Mina LA. Comparison of PARPi efficacy according to homologous recombination deficiency biomarkers in patients with ovarian cancer: a systematic review and meta-analysis. Chin Clin Oncol. 2023 Jun; 12 (3):21 Epub 2023 May 15 View PubMed Batalini F, Mina LA, Mina A. Therapy-related Myeloid Neoplasms Following PARP Inhibitors-Letter. Clin Cancer Res. 2023 Mar 14; 29 (6):1157 View PubMed Menezes MCS, Raheem F, Mina L, Ernst B, Batalini F. PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. Cancers (Basel). 2022 Sep 5; 14 (17) Epub 2022 Sept 05 View PubMed Blum JL, Laird AD, Litton JK, Rugo HS, Ettl J, Hurvitz SA, Martin M, Roche HH, Lee KH, Goodwin A, Chen Y, Lanzalone S, Chelliserry J, Czibere A, Hopkins JF, Albacker LA, Mina LA. Determinants of Response to Talazoparib in Patients with HER2-negative, Germline BRCA1/2-mutated Breast Cancer. Clin Cancer Res. 2022 Jan 28 [Epub ahead of print] View PubMed Loving VA, Luiten RC, Siettmann JM, Mina LA. A Breast Radiology Department-operated, Proactive Same-day Program Identifies Pathogenic Breast Cancer Mutations in Unaffected Women. Acad Radiol. 2020 Dec 15 [Epub ahead of print] View PubMed Litton JK, Hurvitz SA, Mina LA, Rugo HS, Lee KH, Goncalves A, Diab S, Woodward N, Goodwin A, Yerushalmi R, Roche H, Im YH, Eiermann W, Quek RGW, Usari T, Lanzalone S, Czibere A, Blum JL, Martin M, Ettl J. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial. Ann Oncol. 2020 Nov; 31 (11):1526-1535 Epub 2020 Aug 20 View PubMed Chinh K, Secinti E, Johns SA, Hirsh AT, Miller KD, Schneider B, Storniolo AM, Mina L, Newton EV, Champion VL, Mosher CE. Relations of Mindfulness and Illness Acceptance With Psychosocial Functioning in Patients With Metastatic Breast Cancer and Caregivers. Oncol Nurs Forum. 2020 Nov 1; 47 (6):739-752 View PubMed Hong F, Ma D, Wu K, Mina LA, Luiten RC, Liu Y, Yan H, Green AA. Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators. Cell. 2020 Oct 29; 183 (3):835-836 View PubMed Hong F, Ma D, Wu K, Mina LA, Luiten RC, Liu Y, Yan H, Green AA. Precise and Programmable Detection of Mutations Using Ultraspecific Riboregulators. Cell. 2020 Mar 5; 180 (5):1018-1032.e16 Epub 2020 Feb 27 View PubMed Hurvitz SA, Goncalves A, Rugo HS, Lee KH, Fehrenbacher L, Mina LA, Diab S, Blum JL, Chakrabarti J, Elmeliegy M, DeAnnuntis L, Gauthier E, Czibere A, Tudor IC, Quek RGW, Litton JK, Ettl J. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial. Oncologist. 2020 Mar; 25 (3):e439-e450 Epub 2019 Nov 25 View PubMed Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Mina LA, Diab S, Woodward NE, Yerushalmi R, Goodwin A, Blum JL, Martin M, Quek RGW, Tudor IC, Bhattacharyya H, Gauthier E, Litton JK, Eiermann W. Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician's Choice Standard-of-Care Chemotherapy. JNCI Cancer Spectr. 2020 Feb; 4 (1):pkz085 Epub 2019 Oct 21 View PubMed Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke EM, Mina LA, Balmana J, Fasching PA, Hurvitz SA, Wardley AM, Chappey C, Hannah AL, Robson ME, ABRAZO Study Group. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline BRCA1/2 Mutations (ABRAZO). Clin Cancer Res. 2019 May 1; 25 (9):2717-2724 Epub 2018 Dec 18 View PubMed Mina LA, Lim S, Bahadur SW, Firoz AT. Immunotherapy for the Treatment of Breast Cancer: Emerging New Data. Breast Cancer (Dove Med Press). 2019; 11:321-328 Epub 2019 Dec 31 View PubMed Sanders K, Lim S, Ortega S, Gimbel M, Mina L. Exemestane-Induced Eosinophilic Colitis in a Patient with Grade 3 Ductal Carcinoma In-Situ: A Case Report and Review of the Literature. Int J Cancer Clin Res. 2019; 6:104. Tometich DB, Mosher CE, Hirsh AT, Rand KL, Johns SA, Matthias MS, Outcalt SD, Schneider BP, Mina L, Storniolo AMV, Newton EV, Miller KD. Metastatic breast cancer patients' expectations and priorities for symptom improvement. Support Care Cancer. 2018 Nov; 26 (11):3781-3788 Epub 2018 May 07 View PubMed Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, Grischke E, Mina LA, Balmana J, Fasching PA, Bhattacharyya H, Hannah AL, Robson ME, Wardley AM. Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial. Eur J Cancer. 2018 Nov; 104:160-168 Epub 2018 Oct 22 View PubMed Ettl J, Quek RGW, Lee KH, Rugo HS, Hurvitz S, Goncalves A, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Markova D, Bhattacharyya H, Hannah AL, Eiermann W, Blum JL, Litton JK. Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial. Ann Oncol. 2018 Sep 1; 29 (9):1939-1947 View PubMed Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, Fehrenbacher L, Yerushalmi R, Mina LA, Martin M, Roche H, Im YH, Quek RGW, Markova D, Tudor IC, Hannah AL, Eiermann W, Blum JL. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation. N Engl J Med. 2018 Aug 23; 379 (8):753-763 Epub 2018 Aug 15 View PubMed Mosher CE, Secinti E, Li R, Hirsh AT, Bricker J, Miller KD, Schneider B, Storniolo AM, Mina L, Newton EV, Champion VL, Johns SA. Acceptance and commitment therapy for symptom interference in metastatic breast cancer patients: a pilot randomized trial. Support Care Cancer. 2018 Jun; 26 (6):1993-2004 Epub 2018 Jan 12 View PubMed Tanaka H, Phipps EA, Wei T, Wu X, Goswami C, Liu Y, Sledge GW Jr, Mina L, Herbert BS. Altered expression of telomere-associated genes in leukocytes among BRCA1 and BRCA2 carriers. Mol Carcinog. 2018 Apr; 57 (4):567-575 Epub 2018 Jan 05 View PubMed Mosher CE, Daily S, Tometich D, Matthias MS, Outcalt SD, Hirsh A, Johns SA, Rand K, Schneider B, Mina L, Storniolo AM, Newton E, Miller K. Factors underlying metastatic breast cancer patients' perceptions of symptom importance: a qualitative analysis. Eur J Cancer Care (Engl). 2018 Jan; 27 (1) Epub 2016 July 27 View PubMed Kakadia S, Yarlagadda N, Awad R, Kundranda M, Niu J, Naraev B, Mina L, Dragovich T, Gimbel M, Mahmoud F. Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. Onco Targets Ther. 2018; 11:7095-7107 Epub 2018 Oct 17 View PubMed Mosher CE, Tometich DB, Hirsh A, Rand KL, Johns SA, Matthias MS, Outcalt SD, Bricker J, Schneider B, Mina L, Storniolo AM, Newton E, Miller K. Symptom experiences in metastatic breast cancer patients: relationships to activity engagement, value-based living, and psychological inflexibility. Psychooncology. 2017 Nov; 26 (11):1944-1951 Epub 2016 Oct 11 View PubMed de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 Jun; 7 (6):620-629 Epub 2017 Feb 27 View PubMed Mina LA, Yu M, Johnson C, Burkhardt C, Miller KD, Zon R. A phase II study of combined VEGF inhibitor (bevacizumab+sorafenib) in patients with metastatic breast cancer: Hoosier Oncology Group Study BRE06-109. Invest New Drugs. 2013 Oct; 31 (5):1307-10 Epub 2013 June 28 View PubMed Sledge G, Mina L, Storniolo AM. Is HER2 through? Curr Breast Cancer Rep. 2012; 4(3):169-70. Appaiah HN, Goswami CP, Mina LA, Badve S, Sledge GW Jr, Liu Y, Nakshatri H. Persistent upregulation of U6:SNORD44 small RNA ratio in the serum of breast cancer patients. Breast Cancer Res. 2011 Sep 13; 13 (5):R86 Epub 2011 Sept 13 View PubMed Mina LA, Sledge GW Jr. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol. 2011 Jun; 8 (6):325-32 Epub 2011 Apr 19 View PubMed Sledge GW Jr, Jotwani AC, Mina L. Targeted therapies in early-stage breast cancer: achievements and promises. Surg Oncol Clin N Am. 2010 Jul; 19 (3):669-79 View PubMed Mina L, Krop I, Zon RT, Isakoff SJ, Schneider CJ, Yu M, Johnson C, Vaughn LG, Wang Y, Hristova-Kazmierski M, Shonukan OO, Sledge GW, Miller KD. A phase II study of oral enzastaurin in patients with metastatic breast cancer previously treated with an anthracycline and a taxane containing regimen. Invest New Drugs. 2009 Dec; 27 (6):565-70 Epub 2009 Feb 13 View PubMed Mina L, Soule SE, Badve S, Baehner FL, Baker J, Cronin M, Watson D, Liu ML, Sledge GW Jr, Shak S, Miller KD. Predicting response to primary chemotherapy: gene expression profiling of paraffin-embedded core biopsy tissue. Breast Cancer Res Treat. 2007 Jun; 103 (2):197-208 Epub 2006 Oct 13 View PubMed Mina L, Sledge GW Jr. Twenty years of systemic therapy for breast cancer. Oncology (Williston Park). 2006 Jan; 20 (1):25-32; discussion 32-3, 36, 40 View PubMed PST-20521788 Home Publications